Programmed death-ligand 1 (PD-L1) expression and the presence of microsatellite instability (MSI) are established predictive biomarkers (7, 8), tumor-infiltrating immune cells (IC) recently received FDA approval (8–11) and Tumor Mutational Burden (TMB) shows promise but remains under investigation (3, 12, 13). Here, CD274 is linked to neoplasm.